{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:22:54Z","timestamp":1793258574279,"version":"4.5.0"},"reference-count":16,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,5,10]],"date-time":"2012-05-10T00:00:00Z","timestamp":1336608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2012,7]]},"abstract":"Summary<\/jats:title>\n \n Marrow cells from patients with higher\u2010risk myelodysplastic syndrome (\n MDS<\/jats:styled-content>\n ) exhibit constitutive nuclear factor (\n NF<\/jats:styled-content>\n )\u2010\u03baB activation. The proteasome inhibitor, bortezomib, has limited efficacy as a single agent in acute myeloid leukaemia. Its activity on leukaemic cell lines is potentiated by chemotherapy. We treated 43 higher\u2010risk\n MDS<\/jats:styled-content>\n patients with bortezomib (1\u00b75\u00a0mg\/m\n 2<\/jats:sup>\n , days 1, 4, 8 and 11) and low dose cytarabine arabinoside (\n LDAC<\/jats:styled-content>\n ; 10\u00a0mg\/m\n 2<\/jats:sup>\n , then 20\u00a0mg\/m\n 2<\/jats:sup>\n from days 1\u201314), every 28\u00a0d for four cycles. Median follow\u2010up was 29\u00b77\u00a0months. Responses were seen in 12 of the 43 patients (28%), including complete response (\n CR<\/jats:styled-content>\n ,\n n<\/jats:italic>\n \u00a0=\u00a01), marrow\u2010\n CR<\/jats:styled-content>\n (\n n<\/jats:italic>\n \u00a0=\u00a03), partial response (\n PR<\/jats:styled-content>\n ,\n n<\/jats:italic>\n \u00a0=\u00a05) and haematological improvement (\n HI<\/jats:styled-content>\n ,\n n<\/jats:italic>\n \u00a0=\u00a03). Responses were seen in 12 (36%) of the 33 previously untreated patients (11%\n CR<\/jats:styled-content>\n , 13%\n PR<\/jats:styled-content>\n , 2\u00b75%\n HI<\/jats:styled-content>\n ), compared to none in the 12 previously treated patients (\n P<\/jats:italic>\n \u00a0<\u00a00\u00b701). Responders had better overall survival (median 18\u00b72 vs. 10\u00a0months). One\n CR<\/jats:styled-content>\n and 3 marrow\u2010\n CR<\/jats:styled-content>\n s were seen in patients with complex karyotypes. Main toxicity was haematological, responsible for infection in six patients and bleeding in 3. Three patients with Grade 1\u20132 pre\u2010treatment haematotoxicity developed Grade 3\u20134 toxicity. Neuropathy was seen in 12% of patients. The addition of bortezomib to\n LDAC<\/jats:styled-content>\n in higher\u2010risk\n MDS<\/jats:styled-content>\n may improve results obtained with\n LDAC<\/jats:styled-content>\n alone, especially in patients with unfavourable karyotypes.\n <\/jats:p>","DOI":"10.1111\/j.1365-2141.2012.09153.x","type":"journal-article","created":{"date-parts":[[2012,5,10]],"date-time":"2012-05-10T06:23:57Z","timestamp":1336631037000},"page":"232-237","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Bortezomib combined with low\u2010dose cytarabine in Intermediate\u20102 and high risk myelodysplastic syndromes. A phase\n I<\/scp>\n \/\n II<\/scp>\n Study by the\n GFM<\/scp>"],"prefix":"10.1111","volume":"158","author":[{"given":"Shanti","family":"Natarajan\u2010Am\u00e9","sequence":"first","affiliation":[{"name":"Hopitaux Universitaires de Strasbourg Strasbourg France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Park","sequence":"additional","affiliation":[{"name":"H\u00f4tel Dieu de Paris Assistance Publique H\u00f4pitaux de Paris (AP\u2010HP) Universit\u00e9 Paris VI Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Ades","sequence":"additional","affiliation":[{"name":"H\u00f4pital Avicenne AP\u2010HP Universit\u00e9 Paris XIII Bobigny France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Vey","sequence":"additional","affiliation":[{"name":"Institut Paoli Calmettes Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Guerci\u2010Bresler","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire (CHU) Brabois Nancy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Yves","family":"Cahn","sequence":"additional","affiliation":[{"name":"Clinique Universitaire d'H\u00e9matologie H\u00f4pital Michallon Grenoble France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Etienne","sequence":"additional","affiliation":[{"name":"Institut Bergoni\u00e9 Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Bordessoule","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Dupuytren Limoges France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Ravoet","sequence":"additional","affiliation":[{"name":"H\u00f4pital de Jolimont La Louviere Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Legros","sequence":"additional","affiliation":[{"name":"H\u00f4pital de l'Archet Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Cheze","sequence":"additional","affiliation":[{"name":"CHU de Caen Caen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aspasia","family":"Stamatoullas","sequence":"additional","affiliation":[{"name":"Centre Henri Becquerel Rouen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Berger","sequence":"additional","affiliation":[{"name":"CHU de Dijon Dijon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Centre Hospitalier R\u00e9gional Universitaire d'Angers Angers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Charbonnier","sequence":"additional","affiliation":[{"name":"Institut Paoli Calmettes Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Pierre","family":"Chaury","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Dupuytren Limoges France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Braun","sequence":"additional","affiliation":[{"name":"H\u00f4pital Avicenne AP\u2010HP Universit\u00e9 Paris XIII Bobigny France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[{"name":"H\u00f4pital Avicenne AP\u2010HP Universit\u00e9 Paris XIII Bobigny France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Dreyfus","sequence":"additional","affiliation":[{"name":"H\u00f4tel Dieu de Paris Assistance Publique H\u00f4pitaux de Paris (AP\u2010HP) Universit\u00e9 Paris VI Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Groupe Francophone des My\u00e9lodysplasies (GFM)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,5,10]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.08.021"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1982.tb02771.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1989"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210043"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4149"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0508"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210187"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2004.02.002"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08082.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2079"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-005-0135-z"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01703109"},{"issue":"1","key":"e_1_2_8_14_1","article-title":"Effect of proteasome inhibition by Bortezomib on tumor necrosis factor\u2010alpha(TNF\u2010alpha) and apoptosis in patients with myelodysplastic syndromes","volume":"106","author":"Shetty V.","year":"2003","journal-title":"Blood"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.05.018"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1199"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403934"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2012.09153.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2012.09153.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2012.09153.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T03:55:28Z","timestamp":1695614128000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2012.09153.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,10]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.1111\/j.1365-2141.2012.09153.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09153.x","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717948031.793453098","asserted-by":"object"}]},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,10]]},"assertion":[{"value":"2012-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-03-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-05-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}